Desmopresin
Aliases: DDAVP · Minirin
Last verified: 2026-09-23
The short version
A vasopressin analogue without pressor effect — approved for diabetes insipidus, nocturnal enuresis and mild hemophilia A/von Willebrand disease.
Identity & type
- Molecular type
- analog
- Origin
- A vasopressin analogue without pressor effect — approved for diabetes insipidus, nocturnal enuresis and mild hemophilia A/von Willebrand disease.
Mechanism of action
V2 receptor agonist → renal water reabsorption; release of vWF/factor VIII.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. Oral 0.1–0.4 mg; nasal 10–40 mcg; IV/SC for hemostasis.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Oral 0.1–0.4 mg; nasal 10–40 mcg; IV/SC for hemostasis. DDAVP: effectively stops bedwetting and bleeding in von Willebrand disease; the community carefully monitors sodium due to hyponatremia.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
DDAVP: effectively stops bedwetting and bleeding in von Willebrand disease; the community carefully monitors sodium due to hyponatremia.
Protocol — official vs community
Official / label
DDAVP/Minirin: central diabetes insipidus — oral 0.1–0.8 mg/day in divided doses, or nasal 10–40 mcg/day (availability varies by market); nocturnal enuresis (≥6 years) — 0.2–0.6 mg oral at bedtime; hemostasis in mild hemophilia A / von Willebrand disease — 0.3 mcg/kg IV (or SC) peri-procedurally.
- 01Diabetes insipidus: titrate upward from 0.1 mg until urine output/osmolality controlled
- 02Enuresis: start 0.2 mg at bedtime, may increase to 0.6 mg
Duration: Chronic for DI; enuresis courses are typically up to 3 months with reassessment; single-dose around procedures for hemostasis.
The one side effect that matters is hyponatremia from water retention — for enuresis, fluid restriction in the evening before the dose is an explicit label instruction, and serum sodium is monitored. WADA-prohibited as a masking agent.
Community (anecdotal)
No gray-market protocol exists; any self-directed use centers on off-label sleep (reducing nighttime urination) at bedtime oral doses.
- Cycle:
- —
- Break:
- —
Community footprint is negligible and the risk asymmetry is unfavorable: the failure mode (symptomatic hyponatremia) is silent until it is not.
Human evidence
Long-standing standard; new sublingual forms.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Hyponatremia (risk!), headache.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials